Moneycontrol
Get App
Last Updated : Feb 23, 2016 03:55 PM IST | Source: CNBC-TV18

20% of Cipla FY17 revenues to come from US: Chirag Talati

When asked about the Cipla Indore facility, which has come under the USFDA scanner for manufacturing norms violations, Talati reassures that the facility is not a major contributer to Cipla earnings. Hence this news, he feels should not affect sales.


Talking to CNBC TV18, Chirag Talati, Kotak Institutional Equities, says Cipla would get 20 percent of its earnings in FY17 from their US business. This rise in earnings from their US wing comes mainly after the acquisition of InvaGen Pharmaceuticals Inc., a US generic drug company.  

When asked about the company's Indore plant, which has come under the USFDA scanner for manufacturing norms violations, Talati said the facility is not a major contributer to Cipla earnings. Hence this news, he feels should not affect sales.

He suggested buying Cipla at a target price brought down to Rs 700 from Rs 790. He failed to comment about Aurobindo Pharma and Dr Reddys Laboratories.

For entire interview, watch accompanying video.

Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.

First Published on Feb 23, 2016 01:47 pm
Sections
Follow us on